Compare TRS & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRS | FTRE |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2004 | 2023 |
| Metric | TRS | FTRE |
|---|---|---|
| Price | $37.26 | $9.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $41.50 | $15.39 |
| AVG Volume (30 Days) | 413.8K | ★ 2.0M |
| Earning Date | 06-01-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | $645,720,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $5.33 | $2.96 |
| P/E Ratio | $13.12 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $19.45 | $3.97 |
| 52 Week High | $42.00 | $18.67 |
| Indicator | TRS | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 28.61 |
| Support Level | $33.62 | $9.29 |
| Resistance Level | $40.88 | $11.41 |
| Average True Range (ATR) | 1.77 | 0.91 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 29.37 | 25.39 |
TriMas Corp designs, develops and manufactures a diverse set of products primarily for the consumer products, aerospace & defense, and industrial markets . The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.